An ongoing dialogue on HIV/AIDS, infectious diseases,
January 20th, 2011
A New Antiretroviral Drug Class, and a Movie
In my email in-box today was a very odd press release, referring to this paper, just published in PLoS ONE. With the subject line, “Koronis – Clinical Trial Results Demonstrate Promise for First Non-suppressive HIV Drug,” it included the following information:
Recently published Phase 2a clinical trial results show that the frequency of specific, drug-induced mutations in the HIV genome can be significantly increased by administering KP-1461, a drug being developed by Koronis Pharmaceuticals based on its novel Viral Decay Acceleration (VDA) drug mechanism. Koronis is planning a follow-on Phase 2 trial to determine the treatment duration required to achieve a clinically meaningful decrease in a patient’s viral load.
First, you don’t want to be known as a “Non-suppressive HIV drug.” And second, while I get the premise that giving a drug that leads to mutations probably indicates some sort of selection pressure, it’s a long way from this observation to an actual antiviral agent.
But who knows? This may be the next great antiviral drug class, and the phrase “Viral Decay Acceleration” — with its faint echo of 1950s sci-fi movies — sounds incredibly cool. According to the company’s web site, VDA “exploits the strength of a virus – its high mutation rate – to target its collapse.”
So dim the lights, grab some popcorn, and watch the movie here.
Categories: HIV, Infectious Diseases, Research
Tags: antiretroviral therapy, antiviral, HIV, Koronis
You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.
Comments are closed.

Paul E. Sax, MD
Contributing Editor
NEJM Journal Watch
Infectious Diseases
Biography | Disclosures | Summaries
Learn more about HIV and ID Observations.
Search this Blog
Follow HIV and ID Observations Posts via Email
Archives
-
-
From the Blog — Most Recent Articles
- When Required Learning Modules Surprise You (In a Good Way) September 10, 2025
- End-of-Summer Musings — Hepatitis B, Dalbavancin, Alpha-Gal, and More September 4, 2025
- Watching the Chaos at the CDC — with Sadness and Alarm August 29, 2025
- On the Internet, Nobody Read My First Blog August 22, 2025
- Anal Cancer Screening in HIV: When Guidelines Get Ahead of the Evidence August 16, 2025
NEJM Journal Watch — Recent Infectious Disease Articles
- Cefixime: Might It Be an Option for Treating Early Syphilis?
- Should Emergency Departments Offer Routine Vaccines to Adults?
- Should Immunosuppression Be Interrupted During an Infection?
- Is Endotracheal Aspirate Adequate for Diagnosis of Pneumocystis Pneumonia?
- For Early Syphilis, Are Three Doses of Benzathine Penicillin Better Than One?
-
Tag Cloud
- Abacavir AIDS antibiotics antiretroviral therapy ART atazanavir baseball Brush with Greatness CDC C diff COVID-19 CROI darunavir dolutegravir elvitegravir etravirine FDA HCV hepatitis C HIV HIV cure HIV testing ID fellowship ID Learning Unit Infectious Diseases influenza Link-o-Rama lyme disease medical education MRSA PEP PrEP prevention primary care raltegravir Really Rapid Review resistance Retrovirus Conference rilpivirine sofosbuvir TDF/FTC tenofovir Thanksgiving vaccines zoster